Which is better, GMED or PME.AX?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than GMED — 78/100 (B grade) vs 52/100 (C). That said, "better" depends on which framework you trust — GMED wins on none; PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy GMED or PME.AX?

This page is an educational comparison, not investment advice. Both GMED and PME.AX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GMED better than PME.AX for value investing?

On the Buffett-style value-investing framework, PME.AX currently grades higher — 78/100 vs 52/100, a 26-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between GMED and PME.AX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GMED currently scores 52/100 (C grade); PME.AX scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GMED or PME.AX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GMED and PME.AX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GMED or PME.AX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GMED and PME.AX both Healthcare stocks?

Yes — both Globus Medical, Inc. (GMED) and Pro Medicus Limited (PME.AX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GMED vs PME.AX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Globus Medical

GMED$11.14BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$19.91BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

GMED 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

GMED0wins

7winsPME.AX

Warren Buffett

52D

B78

Benjamin Graham

59D

A90

Philip Fisher

64C

A98

Peter Lynch

57D

A100

Joel Greenblatt

39F

B84

Charlie Munger

45D

A91

Terry Smith

50D

A96

Side-by-side metrics

Metric	GMED	PME.AX
Market cap	$11.14B	$19.91B Winner
P/E (TTM)	Winner: 17.7x	147.6x
EV/EBIT	Winner: 20.6x	106.8x
ROIC (TTM)	9.72%	42.56% Winner
Gross margin	67.86%	99.85% Winner
Net margin	18.92%	54.12% Winner
Revenue CAGR 5y	Winner: 32.34%	31.61%
EPS CAGR 5y	28.06%	37.34% Winner
Debt / Equity	0.0x	0.0x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMED leads on

P/E (TTM)17.7xvs 147.6x+88%
EV/EBIT20.6xvs 106.8x+81%

PME.AX leads on

ROIC (TTM)42.56%vs 9.72%+77%
Net margin54.12%vs 18.92%+65%
Debt / Equity0.0xvs 0.0x+64%
Market cap$19.91Bvs $11.14B+44%

More like GMED

GMED vs 1681.HK GMED vs SANOFICONR.NS GMED vs SANOFICONR.BO GMED vs CAMX.ST

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

Read the full Buffett-Brain analysis for GMED Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Globus Medical

GMED$11.14BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$19.91BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

GMED 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

GMED0wins

7winsPME.AX

Warren Buffett

52D

B78

Benjamin Graham

59D

A90

Philip Fisher

64C

A98

Peter Lynch

57D

A100

Joel Greenblatt

39F

B84

Charlie Munger

45D

A91

Terry Smith

50D

A96

Side-by-side metrics

Metric	GMED	PME.AX
Market cap	$11.14B	$19.91B Winner
P/E (TTM)	Winner: 17.7x	147.6x
EV/EBIT	Winner: 20.6x	106.8x
ROIC (TTM)	9.72%	42.56% Winner
Gross margin	67.86%	99.85% Winner
Net margin	18.92%	54.12% Winner
Revenue CAGR 5y	Winner: 32.34%	31.61%
EPS CAGR 5y	28.06%	37.34% Winner
Debt / Equity	0.0x	0.0x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMED leads on

P/E (TTM)17.7xvs 147.6x+88%
EV/EBIT20.6xvs 106.8x+81%

PME.AX leads on

ROIC (TTM)42.56%vs 9.72%+77%
Net margin54.12%vs 18.92%+65%
Debt / Equity0.0xvs 0.0x+64%
Market cap$19.91Bvs $11.14B+44%

More like GMED

GMED vs 1681.HK GMED vs SANOFICONR.NS GMED vs SANOFICONR.BO GMED vs CAMX.ST

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

Read the full Buffett-Brain analysis for GMED Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.